News | August 19, 2024
Aptar’s nasal unidose system delivers FDA-approved neffy
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
New facility is part of Aptar Pharma’s global expansion program
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
Pharmapack trends are a key barometer of global device and packing opportunities in 2022
Subscribe To Our Newsletter & Stay Updated
